HomeCompareCNICF vs ABBV

CNICF vs ABBV: Dividend Comparison 2026

CNICF yields 1.07% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNICF wins by $89.8K in total portfolio value· pulled ahead in Year 9
10 years
CNICF
CNICF
● Live price
1.07%
Share price
$2.35
Annual div
$0.03
5Y div CAGR
69.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$192.1K
Annual income
$100,386.48
Full CNICF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CNICF vs ABBV

📍 CNICF pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNICFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNICF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNICF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNICF
Annual income on $10K today (after 15% tax)
$91.29/yr
After 10yr DRIP, annual income (after tax)
$85,328.51/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CNICF beats the other by $64,272.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNICF + ABBV for your $10,000?

CNICF: 50%ABBV: 50%
100% ABBV50/50100% CNICF
Portfolio after 10yr
$147.2K
Annual income
$62,579.12/yr
Blended yield
42.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CNICF
No analyst data
Altman Z
0.3
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNICF buys
0
ABBV buys
0
No recent congressional trades found for CNICF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNICFABBV
Forward yield1.07%3.06%
Annual dividend / share$0.03$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR69.9%40.6%
Portfolio after 10y$192.1K$102.3K
Annual income after 10y$100,386.48$24,771.77
Total dividends collected$163.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CNICF vs ABBV ($10,000, DRIP)

YearCNICF PortfolioCNICF Income/yrABBV PortfolioABBV Income/yrGap
1$10,882$182.47$11,550$430.00$668.00ABBV
2$11,960$315.31$13,472$627.96$1.5KABBV
3$13,347$550.22$15,906$926.08$2.6KABBV
4$15,256$975.01$19,071$1,382.55$3.8KABBV
5$18,094$1,769.65$23,302$2,095.81$5.2KABBV
6$22,693$3,332.57$29,150$3,237.93$6.5KABBV
7$30,918$6,636.66$37,536$5,121.41$6.6KABBV
8$47,440$14,357.57$50,079$8,338.38$2.6KABBV
9← crossover$85,741$34,980.16$69,753$14,065.80+$16.0KCNICF
10$192,129$100,386.48$102,337$24,771.77+$89.8KCNICF

CNICF vs ABBV: Complete Analysis 2026

CNICFStock

China International Capital Corporation Limited provides financial services in Mainland China and internationally. The company operates through six segments: Investment Banking; Equities; Fixed Income, Commodities, and Currencies (FICC); Asset Management; Private Equity; and Wealth Management. The Investment Banking segment provides investment banking services, including equity financing, debt, and structured financing and financial advisory services. The Equity segment offers investment research, sales, trading, and products and cross-border services, including institutional trading and capital services, such as primary brokerage, over-the-counter derivatives, capital introduction, and market-making transactions. The FICC segment provides fixed-income products, such as interest rate, credit, and structured products, as well as on overseas exchange and commodities. The Asset Management segment engages in the social security and annuity investment management, institutional entrusted investment management, overseas asset management, retail and mutual fund businesses, etc. The Private Equity segment provides corporate equity funds, fund of funds, dollar funds, real estate funds, infrastructure funds, etc. The Wealth Management segment offers wealth transactional, capital, and product configuration services. The company serves domestic and overseas investors, and corporations and institutional clients, as well as retail clients, families, and corporate clients. China International Capital Corporation Limited was incorporated in 1995 and is headquartered in Beijing, the People's Republic of China.

Full CNICF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CNICF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNICF vs SCHDCNICF vs JEPICNICF vs OCNICF vs KOCNICF vs MAINCNICF vs JNJCNICF vs MRKCNICF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.